MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412610 | Name: Cetraxate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cetraxate is a broad spectrum peptide hydrolase inhibitor.

Chemical Structure

Cetraxate
Cetraxate
CAS#34675-84-8 (free base)

Theoretical Analysis

MedKoo Cat#: 412610

Name: Cetraxate

CAS#: 34675-84-8 (free base)

Chemical Formula: C17H23NO4

Exact Mass: 305.1627

Molecular Weight: 305.37

Elemental Analysis: C, 66.86; H, 7.59; N, 4.59; O, 20.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
34675-84-8 (free base) 27724-96-5 (HCl)
Synonym
Cetraxate (free base); Neuer; Cetraxatum
IUPAC/Chemical Name
Benzenepropanoic acid, 4-(((4-(aminomethyl)cyclohexyl)carbonyl)oxy)-, trans-
InChi Key
FHRSHSOEWXUORL-HDJSIYSDSA-N
InChi Code
InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20)/t13-,14-
SMILES Code
O=C(O)CCC1=CC=C(OC([C@H]2CC[C@H](CN)CC2)=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 305.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Katagiri F, Sato Y, Itoh H, Takeyama M. Cetraxate raises levels of calcitonin gene-related peptide and substance P in human plasma. J Pharm Pharmacol. 2004 Apr;56(4):557-61. doi: 10.1211/0022357023169. PMID: 15099451. 2: Kurebayashi Y, Ikeda T, Osada Y. Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats. Jpn J Pharmacol. 1988 Jan;46(1):17-25. doi: 10.1254/jjp.46.17. PMID: 3367546. 3: Kawano S, Hayashi N, Tsuji S, Fusamoto H, Kamada T. Cetraxate improves ethanol-induced gastric mucosal congestion in anesthetized dogs. Jpn J Pharmacol. 1992 Sep;60(1):39-42. doi: 10.1254/jjp.60.39. PMID: 1460803. 4: Suzuki Y, Ito M, Sudo Y. Studies on the mechanism of action of cetraxate [4'-(2-carboxyethyl)phenyl trans-4-aminomethyl cyclohexanecarboxylate hydrochloride], a new anti-ulcer agent. Jpn J Pharmacol. 1979 Dec;29(6):829-38. doi: 10.1254/jjp.29.829. PMID: 161596. 5: Adachi K, Suetsugu H, Moriyama N, Kazumori H, Kawamura A, Fujishiro H, Sato H, Okuyama T, Ishihara S, Watanabe M, Kinoshita Y. Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers. J Gastroenterol Hepatol. 2001 Nov;16(11):1211-6. doi: 10.1046/j.1440-1746.2001.02606.x. PMID: 11903737. 6: Hirano T, Takeuchi S. Anti-ulcer agent, cetraxate hydrochloride (Neuer), prevents subcellular redistribution of lysosomal enzyme in caerulein-induced pancreatitis in the rat. J Int Med Res. 1994 Mar-Apr;22(2):107-12. doi: 10.1177/030006059402200207. PMID: 8020637. 7: Kubota K, Shimizu N, Nozaki K, Takeshita Y, Ueda T, Imamura K, Hiki N, Yamaguchi H, Shimoyama S, MaFune K, Kaminishi M. Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients. Dig Dis Sci. 2005 May;50(5):842-6. doi: 10.1007/s10620-005-2650-5. PMID: 15906755. 8: Tachi K, Goto H, Hayakawa T, Sugiyama S. Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric oxide synthase activity in rats. Aliment Pharmacol Ther. 1996 Feb;10(1):97-103. doi: 10.1111/j.1365-2036.1996.tb00182.x. PMID: 8871449. 9: Kamada T, Haruma K, Miyoshi E, Mihara M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G, Tahara K, Mukai T, Kawamura Y, Hattori N. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. Aliment Pharmacol Ther. 2000 Aug;14(8):1089-94. doi: 10.1046/j.1365-2036.2000.00807.x. PMID: 10930905. 10: Suzuki Y, Hayashi M, Ito M, Yamagami I. Anti-ulcer effects of 4'-(2-carboxyetyl) phenyl trans-4-aminomethyl cyclohexanecarboxylate hydrochloride (cetraxate) on various experimental gastric ulcers in rats. Jpn J Pharmacol. 1976 Aug;26(4):471-80. doi: 10.1254/jjp.26.471. PMID: 1003703.

View History

CL5D

CL5D

New Featured